bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 128,700 shares, a decrease of 20.2% from the September 30th total of 161,300 shares. Based on an average trading volume of 5,000 shares, the short-interest ratio is currently 25.7 days.
bioMérieux Stock Performance
Shares of OTCMKTS BMXMF remained flat at $112.88 during midday trading on Monday. 10 shares of the stock traded hands, compared to its average volume of 359. bioMérieux has a twelve month low of $93.25 and a twelve month high of $122.52. The company's 50-day moving average price is $115.74 and its two-hundred day moving average price is $107.36.
Wall Street Analyst Weigh In
Separately, UBS Group upgraded shares of bioMérieux to a "strong-buy" rating in a report on Thursday, August 22nd.
Get Our Latest Research Report on BMXMF
bioMérieux Company Profile
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider bioMérieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMérieux wasn't on the list.
While bioMérieux currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
